1.1Lipid matrix for release
A spray-chilled blend of glyceryl behenate and dispersed active salt forms solid particles that are blended into the lozenge. As the lozenge dissolves, saliva enters pores in the particles and dissolves the exposed salt.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A spray-chilled blend of glyceryl behenate and dispersed active salt forms solid particles that are blended into the lozenge. As the lozenge dissolves, saliva enters pores in the particles and dissolves the exposed salt.
In 3-(1-methylpiperidin-2-yl)pyridine, the saturated ring contains five carbon atoms and one nitrogen atom. Protonation at the saturated ring nitrogen supplies the positive charge for loading onto a carboxylate resin.
The R5 methyl group preserves a substitution on the scaffold while both R7 and R8 carry hydrogen. The protonated amine binds to a cation-exchange resin, and dissolved ions in saliva drive release.
A carbon–carbon bond joins pyridine C3 to the methylene carbon, and a second carbon–carbon bond joins that carbon to azetidine C2. The azetidine nitrogen supplies a protonation site for binding to a carboxylate resin.
The ring bonds directly to the oxygen of the hydroxyl group, which provides a hydrogen-bond donor for interaction with water. During resin loading, the protonated azetidine nitrogen supplies the charge for association with carboxylate sites.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A pharmaceutical testing laboratory uses the active-loaded resin as a reference specimen for a flow-through dissolution instrument. A weighed portion of resin sits between two porous frits while artificial saliva flows through the cell at a fixed temperature and flow rate. Timed effluent samples provide a release curve that the laboratory compares with a reference curve for the same resin lot.
A crosslinked acrylic cation-exchange resin bearing carboxyl groups serves as the resin base. The sodium-form resin contacts an aqueous solution of the active at a pH where the resin carries carboxylate groups and the active carries a positive charge. The active displaces sodium on the resin, and filtration and rinsing separate the loaded particles from dissolved material. Saliva supplies exchangeable cations that displace the bound active during use.
The same resin grade is sieved into 150–250 micrometre and 425–600 micrometre fractions before loading. Each fraction is loaded separately to the same active content per gram of dry resin, then the fractions are blended at a 30:70 dry mass ratio and sealed in a permeable oral pouch. Saliva wets both fractions through the pouch wall, and the smaller particles provide shorter diffusion paths for the dissolved active.
A bilayer rotary tablet press places a rapidly dispersing layer of loaded resin granules against an inactive, slowly eroding cellulose layer. The press lightly compacts the first fill, adds the second fill, and compresses both layers together. The loaded layer breaks up during oral use and exposes the resin particles to saliva while the cellulose layer erodes.
A fluidized-bed coater applies a film of ethylcellulose and water-soluble polyethylene glycol to the loaded resin granules. The coater dries the granules to a specified coating mass gain, and the coated granules are filled into a saliva-permeable pouch. Saliva dissolves the polyethylene glycol and opens pores through which ions enter the coating and released active diffuses out.
A stirred loading vessel holds the resin slurry and feeds a filtered liquid sample through an automated sampler to a liquid chromatograph with ultraviolet detection. Control software calculates the mass of dissolved active from the measured concentration and the current liquid volume, accounting for active removed in earlier samples. The software opens the vessel outlet to a solids filter after the calculated resin loading reaches the batch target and successive readings stabilize within a preset tolerance.
R8 is ethyl (–CH2CH3), a two-carbon alkyl group attached through its methylene carbon. R7 is hydrogen.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Y represents 6-halopyridin-3-yl, 6-(C1-C4)alkylpyridin-3-yl, 6-halo(C1-C4)alkylpyridin-3-yl, 6-(C1-C4)alkoxypyridin-3-yl, 6-halo(C1-C4)alkoxypyridin-3-yl, 2-chlorothiazol-4-yl, or 3-chloroisoxazol-5-yl when n=0-3 and L represents a single bond, or Y represents hydrogen, C1-C4 alkyl, phenyl, 6-halopyridin-3-yl, 6-(C1-C4)alkylpyridin-3-yl, 6-halo(C1-C4)alkylpyridin-3-yl, 6-(C1-C4)alkoxypyridin-3-yl, 6-halo(C1-C4)alkoxypyridin-3-yl, 2-chlorothiazol-4-yl, or 3-chloroisoxazol-5-ylA · US 2009/0325892 A1 · claim 1
In the aforementioned exemplary substitutents, groups such as alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, heterocycle and aryl can themselves be optionally substituted.B · US 2019/0263768 A1 · ¶ 115
An alternative method for the preparation of sulfides of formula (A4), wherein R1, S and L taken together form a ring, n=0, m=0, and Y=6-halo, 6-(C1-C4)alkyl, 6-(C1-C4)haloalkyl or 6-(C1-C4)alkoxy substituted 3-pyridyl is highlighted in Scheme H.A · US 2009/0325892 A1 · ¶ 33
Y represents 6-halopyridin-3-yl, 6-(C1-C4)alkylpyridin-3-yl, 6-halo(C1-C4)alkylpyridin-3-yl, 6-(C1-C4)alkoxypyridin-3-yl, 6-halo(C1-C4)alkoxypyridin-3-yl, 2-chlorothiazol-4-yl, or 3-chloroisoxazol-5-yl when n=0-3 and L represents a single bond, or Y represents hydrogen, C1-C4 alkyl, phenyl, 6-halopyridin-3-yl, 6-(C1-C4)alkylpyridin-3-yl, 6-halo(C1-C4)alkylpyridin-3-yl, 6-(C1-C4)alkoxypyridin-3-yl, 6-halo(C1-C4)alkoxypyridin-3-yl, 2-chlorothiazol-4-yl, or 3-chloroisoxazol-5-ylA · US 2009/0325892 A1 · claim 1
In the aforementioned exemplary substitutents, groups such as alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, heterocycle and aryl can themselves be optionally substituted.B · US 2019/0263768 A1 · ¶ 115
R8 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, aryl or substituted aryl, alkylaryl or substituted alkylaryl;B · US 2019/0263768 A1 · ¶ 47
Y represents 6-halopyridin-3-yl, 6-(C1-C4)alkylpyridin-3-yl, 6-halo(C1-C4)alkylpyridin-3-yl, 6-(C1-C4)alkoxypyridin-3-yl, 6-halo(C1-C4)alkoxypyridin-3-yl, 2-chlorothiazol-4-yl, or 3-chloroisoxazol-5-yl when n=0-3 and L represents a single bond, or Y represents hydrogen, C1-C4 alkyl, phenyl, 6-halopyridin-3-yl, 6-(C1-C4)alkylpyridin-3-yl, 6-halo(C1-C4)alkylpyridin-3-yl, 6-(C1-C4)alkoxypyridin-3-yl, 6-halo(C1-C4)alkoxypyridin-3-yl, 2-chlorothiazol-4-yl, or 3-chloroisoxazol-5-ylA · US 2009/0325892 A1 · claim 1
An empty cell means only that no passage was reproduced there.
Insects are developing resistance to pesticides in current use.A · US 2009/0325892 A1 · ¶ 4
Therefore, a need exists for new pesticides and particularly for pesticides that have new modes of action.A · US 2009/0325892 A1 · ¶ 4
The present invention relates to a novel class of compounds as Stat3 pathway inhibitors, cancer stem cell inhibitors as well as cancer stem cell pathway inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to synthesis and pharmaceutical compositions containing such compounds.B · US 2019/0263768 A1 · ¶ 2
Therefore, Stat3 inhibitors may be used to prevent and treat autoimmune and inflammatory diseases as well as the other diseases listed above that are caused by inflammation.B · US 2019/0263768 A1 · ¶ 6
patent.fyi, US 2026/0354442 A1, claim 1, first published 2026-11-18T23:03:08-05:00, https://patent.fyi/US20260354442/, SHA-256 52e2a5d9921f07fe3a8121ce9cf12c2a83889c4849d53527b5e811651f7b6a4b